# A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Study · id `cardio:ct-nct06749457` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06749457](<https://clinicaltrials.gov/study/NCT06749457>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06749457

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 242 participants.

## Technical summary

Registry record NCT06749457. Randomized; quadruple masking; primary purpose prevention. Start 2024-12-30 (actual); primary completion 2027-03-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 1/2
- Enrolled: 242 participants (enrolled count; ClinicalTrials.gov record NCT06749457, source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)
- Started: 2024-12-30 (actual) (ClinicalTrials.gov record NCT06749457, source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2027-03-08 (anticipated) (ClinicalTrials.gov record NCT06749457, source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)
- Completion: 2027-12-13 (anticipated) (ClinicalTrials.gov record NCT06749457, source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06749457, source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06749457-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
- Acronym: PEAK
- Condition: Staphylococcus Aureus
- Intervention (Drug): AZD7760
- Intervention (Other): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Parexel
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Parexel (`cardio:org-parexel`)

## Provenance

Content hash: 2c52a2c29c5fb7dcd4d2f821197bd278632f332570cda3ea97735fe14da3f41e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
